Major US Insurer Now Covers Breakthrough Treatment for Chronic Lower Back Pain

Major US Insurer Now Covers Breakthrough Treatment for Chronic Lower Back Pain

Christina Sanchez
Christina Sanchez
2 Min.
A detailed line drawing of a woman's torso with the cervical spine highlighted, including bones, ligaments, and tendons, accompanied by text and numbers related to a patent drawing.

Major US Insurer Now Covers Breakthrough Treatment for Chronic Lower Back Pain

A major US health insurer has begun covering a new treatment for chronic lower back pain. The policy, introduced by Health Care Service Corporation (HCSC), took effect on 1 December 2025. It now applies to over 26 million people across the country.

The Intracept Procedure is an FDA-approved, minimally invasive treatment for patients with vertebrogenic pain. This condition affects roughly one in six people with chronic lower back pain, a group totalling around 30 million in the US. Unlike standard therapies, Intracept specifically targets the vertebrae as the pain source.

Two large clinical trials have proven its long-term benefits. Patients reported lasting improvements in pain and mobility after just one session. The procedure also requires no hospital stay, making it a convenient option for those who have tried other treatments without success.

Mary Hailey, Vice President of health economics at Boston Scientific, called the decision a significant step. She noted that more commercial insurers are now recognising Intracept's clinical value. The move follows years of research, including studies showing its safety and durability over time.

HCSC's new policy expands access to Intracept for eligible patients. The treatment offers an alternative for those struggling with vertebrogenic pain. With broader insurance support, more people may now benefit from this targeted approach.

Neueste Nachrichten